HER2-Positive Breast Carcinoma — Trials

HER2-Positive Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 140
Recruiting: 73
Ph III recruiting: 15
Growth YoY: +11.5%
Industry share: 19%
Top sponsor: Fudan University
Termination share: 43.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05378464	Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer	suspended	Phase 1	28	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Sep 15, 2026	clinicaltrials
NCT04120246	Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer	suspended	Phase 1	24	Veana TherapeuticsINDUSTRY	1	Jul 10, 2024